stockrowLiquidia Corporation
LQDA Healthcare Drug Manufacturers Specialty & Generic
Liquidia Corporation’s revenue for fiscal 2025 (year ended December 2025) was $158.3 million, up 1,031.2% from fiscal 2024.
- Revenue
- +1,842.7%
- EPS
- +271.4%
- Free cash flow
- +270.2%
- Total debt
- −9.04%
Quarter to June 2026, against a year earlier
Follow LQDA
Alert me
Liquidia Corporation (LQDA) Net income
Liquidia Corporation's net income for fiscal 2025 was −$68.9M, compared with −$128.3M in fiscal 2024. Over the twelve months to 30 June 2026 it was $138.6M. Over the past ten years it has ranged from −$128.3M (fiscal 2024) to −$15.9M (fiscal 2016); the current reading is higher than 27% of that period. Liquidia Corporation ranks 14th of 84 Drug Manufacturers Specialty & Generic companies by net income.
Net income, annual
Embed this chart
Annual newest first
| Period | Net income | Change |
|---|---|---|
| FY2025 | −$68.9M | — |
| FY2024 | −$128.3M | — |
| FY2023 | −$78.5M | — |
| FY2022 | −$41.0M | — |
| FY2021 | −$34.6M | — |
| FY2020 | −$59.8M | — |
| FY2019 | −$47.6M | — |
| FY2018 | −$53.1M | — |
| FY2017 | −$29.2M | — |
| FY2017 | −$29.2M | — |
Quarterly newest first
| Period | Net income | Change |
|---|---|---|
| Jun 2026 | $74.7M | 41.35% |
| Mar 2026 | $52.9M | 263.19% |
| Dec 2025 | $14.6M | — |
| Sep 2025 | −$3.5M | — |
| 33 more quarters | Free account |
Against its own ten years
Net income against peers
| Company | Net income |
|---|---|
| HCM HUTCHMED (China) Limited Sponsored ADR compare | $967.7M |
| SUPN Indivior Pharmaceuticals Inc. compare | $450.0M |
| LNTH Lantheus Holdings, Inc. compare | $269.9M |
| AMRX AMNEAL PHARMACEUTICALS, INC. compare | $209.5M |
| PBH Prestige Consumer Healthcare Inc. compare | $155.1M |
| LQDA Liquidia Corporation | $138.6M |
| RGC Regencell Bioscience Holdings Limited compare | −$14.0M |
| HIMS Hims & Hers Health, Inc. compare | −$142.0M |
| AMLX Amylyx Pharmaceuticals, Inc. compare | −$152.1M |
What Net income is
Net Income tells an investor how much profit a company kept in a period after every cost, interest charge and tax.
Reported line item
More on LQDA
- Revenue
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement